Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

Sponsor
Pfizer
Study ID
NCT04517669
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis in order to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and Quality of Life, in a real-world setting over a 12-month observation period

Key Dates

Start date
May 17, 2021
Status verified
Sep 2025
Primary completion
Jul 30, 2024
Completion
Jul 30, 2024

Study Design

Enrollment
116 participants (actual)

Primary Outcome Measure

Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 [ Time Frame: At Month 6 ]

Related Studies